Language of Resource
Full Text Available
Open Access / OK to Reproduce
This cross-sectional study investigates the impact of benzodiazepine (BZD) use in opioid agonist treatment (OAT) patients on their quality of life (QoL).
The association of lower QoL and BZD use in OAT patients is strongly confounded by co-occurring depressive state and psychiatric symptoms.
Survey using a convenience sample (n=141)